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Cutaneous features with respect to lesion morphology,
location, and time of onset following transplantation were
collected for each patient and further stratiﬁed by aGVHD
clinical grade.
Results: For all cutaneous aGVHD patients (n¼37), the onset
of rash was on average, day +45 (range +4 to +153). The most
common skin lesion morphology was morbilliform (55%)
followed by patchy erythema (38%). Follicular accentuation
was seen in 29% of rashes. The cutaneous eruptions most
commonly occurred on the trunk (69%), arms/legs (67%), face
(62%), ears (38%) and palms (38%).
Comparing grade I and II skin aGVHD patients, grade I
patients (n¼11) had more patchy erythema (73% vs 23%,P ¼
.008), purpuric/violaceous lesions (55% vs 15%,P ¼ .038) or
a reticular pattern (36% vs 0%,P ¼ .005) than grade II patients
(n¼26). Grade II aGVHD patients were found to have cuta-
neous eruptions located more often on the trunk (85% vs
36%,P ¼ .006) and arms/legs (77% vs 36%,P ¼ .028) when
compared to grade I aGVHD patients. Comparison to grade III
(n¼3) and IV (n¼2) aGVHD patients was not performed given
the paucity of cases.
Conclusion: We proﬁled the salient cutaneous features
associated with aGVHD and their relative incidences based
on clinical grade, skin lesion morphology and anatomic site
of involvement. Application of this analysis will allow for
improvements in the diagnosis of aGVHD and differentiation
from other clinical mimickers. Differences in lesional
morphology and location may differentiate grade I and II
cutaneous aGVHD and serve to guide appropriate treatment.427
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Background: Lipoxins (derived from arachidonic acid) and
the resolvins and protectins (derived from u3-poly-
unsaturated fatty acids (PUFAs)) are endogenously produced
lipid mediators with potent anti-inﬂammatory and tissue
healing properties. Acetylsalicylic acid (ASA, aspirin) results
in the synthesis of aspirin-triggered lipoxins, isomers for
these lipid mediators with identical anti-inﬂammatory
actions. In part, these lipid mediators act through down-
regulation of Th1 cytokines known to be important in aGVHD
pathogenesis. The C56BL/6/(C57BL/6 x DBA/2)F1-hybrid is
a major histocompatibility mismatched mouse model of
lethal aGVHD (similar to a non T-cell depleted HLA hap-
loidentical BMT without GVHD prophylaxis) that allows
isolation of the aGVHD effect. We wanted to test whether
these novel lipid mediators could attenuate aGVHD in this
highly inﬂammatory allogeneic transplant mouse model.
Methods: Mice were transplanted according to standard
protocols. Four diets were created, including a control diet
containing 2% u6-PUFAs; and three experimental diets,
enriched for (1) 2%u3-PUFAs (2) 2%u6-PUFAs plus ASA (0.02
mg/g of feed) (3) 2%u3-PUFAs plus ASA. Micewere randomly
fed one diet (n¼10-12 per group) for 8-weeks beforetransplant and the same diet after transplant. A separate
experiment conﬁrmed that feeding the different diets for 8-
weeks before transplant resulted in differential tissue (liver)
stores of u6- and u3-PUFAs. A ﬁfth group (n¼10) was fed the
control diet but injected with the aspirin-triggered lipoxin
15-epi-LxA4 IV on day 0 and IP on day 7 (200 mcg/kg/dose).
The primary outcome was days before the onset of aGVHD-
associated morbidity (humane end point) post-transplant.
Results: Control GVH mice met the humane end-point for
euthanasia as result of aGVHD at a median of 14 days post-
transplant (range: 9-16 days). Kaplan-Meier survival curves
showed modest but statistically signiﬁcant improvements in
survival for mice fed a diet enriched for u3-PUFAs plus ASA
(P¼ .0117) andmice receiving the aspirin-triggered lipoxin (P
¼ .034) compared to the control group. Survival improve-
ments and the onset of lethal aGVHD were delayed by
a matter of days for the mice receiving the interventions.
Conclusion: We provide proof-of-principle that dietary u3-
PUFAs, aspirin, and aspirin-triggered lipoxinsmay offer novel
ways to counteract aGVHD. Our interventions approximate
acceptable human dietary intake for u3-PUFAs and taking
a baby-aspirin once per day. Further experiments using
different aGVHD mouse models are planned.428
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CGVHD develops in more than 50% of survivors of allogeneic
stem cell transplantation and is responsible for mortality in
one third of patients. Long term immunosuppressive therapy
with steroids is the standard treatment. ECP has shown
activity in acute and cGVHD and is successful in about 50% of
the patients after 3 e 6 months of therapy. We studied the
cytokine proﬁles in 6 patients with cGVHD undergoing ECP. A
comprehensive assessment of organ system involvement
using NIH Consensus response assessment tools was done at
study entry and at six months. Patients underwent ECP
treatments twice on two consecutive days every two weeks
for 3 to 6 months. All patients underwent baseline, two-
months, four months and six-month assessments. 10 ml of
leukopheresed blood was obtained from the ECP machine
prior to the initiation of ECP at baseline, and at 2, 4 and 6
months post treatment to assess peripheral blood B and T
cells and the cytokine analysis. CD4+ T cells were puriﬁed
from PBMCs and stimulated with anti-CD3 and anti-CD28 for
ﬁve days. Tissue culture supernatants were collected and
analyzed for the production of 42 cytokines using Luminex
technology. Three patients responded to treatment with ECP
and three did not and later received other therapies. We have
previously reported that responding patients had higher
CD4+CD25+FoxP3+ cells. Of the cytokines analyzed, soluble
CD25 and TNFbwere secreted at signiﬁcantly higher levels in
responding patients prior to ECP initiating therapy (Figure).
In responders, sCD25 and TNFb levels remained high
